Rajan Ragupathy
Rajan Ragupathy
Clinical Trials and Research Pharmacist, Waikato District Health Board, New Zealand
Verified email at waikatodhb.health.nz
TitleCited byYear
A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand
R Ragupathy, K Aaltonen, J Tordoff, P Norris, D Reith
Pharmacoeconomics 30 (11), 1051-1065, 2012
452012
The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand
K Aaltonen, R Ragupathy, J Tordoff, D Reith, P Norris
Value in Health 13 (1), 148-156, 2010
272010
KEY INFORMANTS’PERCEPTIONS OF HOW PHARMAC OPERATES IN NEW ZEALAND
R Ragupathy, J Tordoff, P Norris, D Reith
International journal of technology assessment in health care 28 (4), 367-373, 2012
132012
Access to children’s medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007
R Ragupathy, J Tordoff, P Norris, D Reith
Pharmacy world & science 32 (3), 386-393, 2010
122010
Pharmaceutical pricing in New Zealand
R Ragupathy, K Kilpatrick
Pharmaceutical Prices in the 21st Century, 189-207, 2015
72015
New Zealanders’ access to licensed and subsidised medicines compared with a nationwide single payer system in each of Australia, the United Kingdom and the United States
Y Ragupathy
University of Otago, 2013
72013
Coverage and accuracy of ethnicity data on three Asian ethnic groups in New Zealand
P Norris, S Horsburgh, P Padukkage, NY Baik, D Kim, A Fussell, ...
Australian and New Zealand journal of public health 34 (3), 258-261, 2010
72010
Applying the Reason Model to enhance health record research in the age of'big data'.
R Ragupathy, V Yogarajan
62018
Exploring pharmacists' opinions regarding PHARMAC's interventions in promoting brand changes
ZU Babar, A Polwin, SW Kan, N Amerasinghe, S McCarthy, F Rasheed, ...
Research in Social and Administrative Pharmacy 11 (1), 96-110, 2015
62015
Comparing the reimbursement of new medicines between Australia and New Zealand
R Ragupathy
Australian Health Review 40 (1), 118-119, 2016
22016
Prostate cancer screening and ethical use of limited resources
R Ragupathy, DB Menkes
The New Zealand Medical Journal (Online) 126 (1385), 2013
22013
Randomized controlled phase II trial of simvastatin as prophylaxis against radiation-induced skin toxicity in breast cancer patients.
S Joseph, G Round, MB Jameson, JM Boyd, R Ragupathy
Journal of Clinical Oncology 31 (15_suppl), TPS1143-TPS1143, 2013
22013
The Authors’ Reply to Wonder and Milne:“Comparing Subsidized Access to Medicines Across Payer Systems”
R Ragupathy, K Aaltonen, J Tordoff, P Norris, D Reith
PharmacoEconomics 31 (2), 175-176, 2013
12013
Health information research privacy standards should include Māori perspectives on privacy
R Ragupathy, V Yogarajan, C Luoni
New Zealand Medical Association 132 (1494), 64-67, 2019
2019
Adoption of international privacy standards in New Zealand health information research.
V Yogarajan, R Ragupathy
2019
Research using electronic health records: not all de-identified datasets are created equal
V Yogarajan, R Ragupathy
CSIRO Publishing 11 (1), 14-15, 2019
2019
Pharmaceutical funding decisions must balance therapeutic innovation, opportunity costs and patient equity
R Ragupathy, M Jameson
The New Zealand Medical Journal (Online) 129 (1440), 22, 2016
2016
Defence of the Living Dead: zombies as vectors for transmitting positive health messages
R Ragupathy
The New Zealand Medical Journal (Online) 129 (1435), 95, 2016
2016
Uptake of new medicines: the Pharmaceutical Management Agency of New Zealand (PHARMAC) in the international context
R Ragupathy
The New Zealand Medical Journal (Online) 128 (1416), 81, 2015
2015
New Zealand consumers’ perceptions of private insurance for pharmaceuticals
R Ragupathy, W Mirza, M Daiya, H Chandra, A Yousif, M Girn
SpringerPlus 3 (1), 1-6, 2014
2014
The system can't perform the operation now. Try again later.
Articles 1–20